Christopher Pierce, EVP and Chief of Business Oper at Prelude Therapeutics Inc (PRLD), sold 27,070 shares at $41.52 ($1.1M) on 2021-09-02, disclosed to the SEC on 2021-09-07.
Open-market sale of $1.1M PRLD by EVP and Chief of Business Oper. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.29 | 3,343 | $135K | 12.0% |
| 2 | $40.29 | 3,343 | $135K | 12.0% |
| 3 | $41.52 | 6,727 | $279K | 24.9% |
| 4 | $41.52 | 6,727 | $279K | 24.9% |
| 5 | $42.50 | 6,930 | $295K | 26.2% |
| Total | $41.47 avg | 27,070 |
| $1.1M |
| 100% |
| Filing → |
| PRLD | SELL | 2021-04-09 | $33K | — | Filing → |
| PRLD | BUY | 2020-09-29 | $71K | — | Filing → |